A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label Phase I/II study, with a dose escalation part (Phase I) and a
single-arm part (Phase II), in patients with recurrent SCLC who progressed after first-line
platinum-based chemotherapy and who are candidates for second line therapy. No PK evaluation
is planned in this study as nivolumab and ipilimumab are unlikely to alter plinabulin's PK,
since the route of excretion is different.